Screening neonatal cord blood for SARS-CoV-2 specific IgA along with IgG and IgM antibodies can be a reliable strategy to identify newborns with serological markers of potential in utero infection so that they can be followed more closely and evaluated over time for infant outcomes. The gene discussed is CD40LG; the disease is infection.